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Abstract: Due to the increased popularity of herbomineral preparations in the healthcare sector, a new proprietary herbomineral 
formulation was formulated consisting of ashwagandha root extract and three minerals viz. zinc chloride, magnesium gluconate, 
and sodium selenate. The objective of the study was to evaluate the in vitro effect of Biofield Energy Healing (The Trivedi 
Effect
®
) on the test formulation using murine splenocyte cells. The herbomineral formulation was divided into two parts; one 
defined as the control, while the other part was treated with the Biofield Energy Healing Treatment performed from a remote 
distance by twenty renowned Biofield Energy Healers (The Trivedi Effect
®
) and defined as the Biofield Treated formulation. The 
splenocyte cells were exposed to test formulations at concentration from 0.00001053 to 10.53 µg/mL and were analyzed after 48 
hours for cell viability using MTT assay. The expression of the cytokines (TNF-α, IFN-γ, IL-1β, and MIP-1α) was determined 
using ELISA assay. The cell viability data showed that all the tested concentration ranges were found to be safe with percentage 
cell viability at more than 80%. Further, TNF-α expression was significantly inhibited in the Biofield Treated test formulation 
group with respect to the vehicle control, while at 0.001053 and 0.1053 µg/mL, the expression was suppressed by 1.70% and 
8.16%, respectively in the Biofield Treated test formulation compared to the untreated formulation. However, a significant 
immunosuppression was reported in IFN-γ expression at 0.00001053, 0.0001053, 0.01053, 0.1053, and 1.053 µg/mL by 12.63%, 
2.31%, 8.31%, 9.15%, and 7.86%, respectively in the Biofield Treated test formulation compared with the untreated test 
formulation. The MIP-1α expression was inhibited by 8.31%, 21.53%, and 8.70% at 0.0001053, 0.01053, and 0.1053 µg/mL, 
respectively in the Biofield Treated formulation compared with the untreated test formulation. However, IL-1β expression was 
significantly suppressed by 19.72% at concentration 0.00001053 µg/mL in the Biofield Treated test formulation compared with 
the untreated test formulation. Thus, the down-regulation of tested cytokines and chemokines in the Biofield Energy Healing test 
formulation might be applicable for controlling acute and chronic inflammation in many clinical diseases. Overall, the results 
demonstrated that The Trivedi Effect
®
- Biofield Energy Healing (TEBEH) has the capacity to potentiate the immunomodulatory 
activity of the test formulation, which can be useful against autoimmune disorders. Biofield Treated Test formulation may also be 
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useful in anti-aging, anti-inflammatory, stress management and in preventing immune-mediated tissue damage in organ 
transplants by improving overall health and quality of life. 
Keywords: Biofield Energy Healing Treatment, The Trivedi Effect®, Herbomineral Formulation, Immune-Modulation,  
Pro-inflammatory Cytokines, Splenocytes 
 
1. Introduction 
Herbomineral formulations have always been a major target 
of scientific research for significant immunomodulatory 
potential. The healing properties of plants and their extracts 
have been recognized and utilized worldwide since ancient 
times. Plant products and their extracts are used in both 
allopathic health care as well as complementary and alternative 
health care in order to improve overall health and the immune 
system [1, 2]. However, much attention has been focused on 
discovering herbal products with immunomodulatory activity 
along with low toxicity and better bioavailability [3]. Many 
scientific studies have identified the immunomodulatory 
properties of medicinal plants, which can be further potentiated 
with the addition of some minerals that regulate the immune 
cells. These types of formulations are commonly defined as 
herbomineral formulations and are the major target for 
pharmaceutical companies as phytopharmaceutical products or 
as dietary supplements. Based on the literature, a new 
proprietary herbomineral formulation was formulated with a 
combination of the herb ashwagandha root extract and three 
minerals viz. zinc, magnesium, and selenium. All the 
ingredients of the formulation in this present study possess 
important activities such as immune-modulatory, anti-
inflammatory, antioxidant, anti-infective, and anti-viral 
properties [4-7]. Withania somnifera (ashwagandha) biological 
activity is mainly reported due to the presence of withanolides, 
and it is used as complementary medicine in alternative 
therapies [8, 9]. Apart from its common attributes such as 
antibacterial, immunomodulatory and antitumor effects, many 
clinical and preclinical data have been available with respect to 
its immunomodulatory impact [4, 10]. The importance of 
minerals such as selenium, zinc, and magnesium is to 
modulate the immune system because their synergistic impact 
has been well-defined [5]. 
Scientific research has documented that in the presence of 
minerals, herbal medicines have been found to exhibit a high 
level of phagocytic index and improved antibody titre [11]. 
These formulations can be used for better therapeutic effect in 
immune compromised patients affected with cardiovascular 
diseases, age and stress related diseases, cancer, and 
autoimmune disorders. Along with herbomineral formulations, 
the Biofield Energy Healers in this study have used energy 
medicine (Biofield Energy Healing Treatment) as a 
complementary and alternative approach to study the impact of 
Biofield Treatment on the herbomineral formulation for its 
immunomodulatory potential with respect to the pro-
inflammatory cytokines in splenocyte cells isolated from mice. 
According to the scientific studies and clinical trials, 
Biofield Energy Treatment has been reported to have 
significant outcome in terms of enhanced immune function of 
cervical cancer patients with therapeutic touch [12], massage 
therapy [13], etc. The National Center of Complementary and 
Integrative Health (NCCIH) has recognized and accepted 
Biofield Energy Healing as a complementary and alternative 
medicine (CAM) health care approach in addition to other 
therapies, medicines and practices such as Tai Chi, yoga, deep 
breathing, natural products, Qi Gong, massage, 
chiropractic/osteopathic manipulation, acupuncture, 
acupressure, meditation, mindfulness, healing touch, special 
diets, naturopathy, progressive relaxation, homeopathy, guided 
imagery, relaxation techniques, hypnotherapy, movement 
therapy, pilates, rolfing structural integration, Ayurvedic 
medicine, traditional Chinese herbs and medicines, 
aromatherapy, essential oils, cranial sacral therapy, applied 
prayer (as is common in all religions, like Buddhism, 
Hinduism, Christianity and Judaism), and Reiki. To this day, 
Biofield Energy Healing has had significant impact in the 
transformation of living organisms and nonliving materials 
including metals, ceramics, polymers, chemicals, and 
pharmaceutical compounds. Human Biofield Energy has subtle 
energy that has the capacity to work in an effective manner 
[14]. Reports showed that Complementary and Alternative 
Medicine (CAM) therapies have been practiced worldwide 
with reported clinical benefits in different health disease 
profiles [15]. This energy can be harnessed and transmitted by 
individuals into living and non-living things via the process of 
Biofield Energy Healing. Biofield Energy Treatment (The 
Trivedi Effect
®
) has been extensively studied with significant 
outcomes in many scientific fields such as cancer science [16, 
17], altering microbial characteristics and features including 
changing the microbial sensitivity of pathogenic microbes in 
microbiology [18-21], genetics [22, 23], altered physical and 
chemical compounds in pharmaceutics [24-27], improved the 
overall productivity, quality and yield of crops and plants in 
agricultural science [28-31], and in materials science where 
The Trivedi Effect
®
 has demonstrated its ability to alter the 
structural, thermal and physical properties of metals, polymers, 
chemicals and ceramics [32-35]. 
The authors of this study sought to evaluate the impact of 
Biofield Energy Treatment (The Trivedi Effect
®
) on the given 
herbomineral formulation, which might improve the 
immunomodulatory function in in vitro cellular model on 
mice splenocyte cells. 
2. Materials and Methods 
2.1. Chemicals and Reagents 
Lipopolysaccharide (LPS), 3-(4, 5-diamethyl-2-thiazolyl) 
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2, 5 diphenyl-2 H-tetrazolium) (MTT), Roswell Park 
Memorial Institute (RPMI-1640), L-glutamine, penicillin, 
streptomycin, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), 2- mercaptoethanol, concanavalin A (Con-A), 
rapamycin, NaHCO3, and EDTA were purchased from Sigma 
Chemical Corp. (St. Louis, MO), a subsidiary of Sigma-
Aldrich Corporation. ELISA (enzyme-link immunosorbent 
assay) assay kits for all cytokines tumor necrosis factor alpha 
(TNF-α), macrophage inflammatory protein-1α (MIP-1α), 
and interleukin-1 beta (IL-1β) were purchased from R&D 
Systems, USA. Fetal bovine serum (FBS) was purchased 
from GIBCO, USA. Ashwagandha (Withania somnifera) root 
extract powder (≥ 5% of total withanolides) was procured 
from Sanat Products Ltd., India. Zinc chloride and 
magnesium (II) gluconate hydrate were procured from Tokyo 
Chemical Industry Co., Ltd. (TCI), Japan. Sodium selenate 
was procured from Alfa Aesar, USA. All other chemicals 
used were of analytical grade available in India. 
2.2. Test Formulation and Reference Standard 
The test formulation contained a combination of four 
ingredients: ashwagandha root powder extract, zinc chloride, 
sodium selenate, and magnesium gluconate. LPS was used as 
an inflammatory stimulant, while Con-A and rapamycin were 
used as a reference standard (positive control) for 
immunostimulatory and immunosuppressive action 
respectively in splenocytes assay. 
2.3. Experimental Animal 
C57BL/6 male mice (8 weeks old, 22 gm body weight) 
were purchased from Vivo Bio Tech Ltd., Hyderabad, India 
and acclimatized for one week prior to the experiments. The 
mice were maintained under controlled conditions with a 
temperature of 22 ± 3°C, humidity of 30% to 70% and a 12-
hours light/12-hours dark cycle and laboratory rodent diet 
and drinking tap water were provided ad libitum. All the 
procedures were in strict accordance with the Guide for the 
Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH). The approval of the 
Institutional Animal Ethics Committee (IAEC) was obtained 
prior to carrying out the animal experiment. 
2.4. Biofield Energy Healing Strategies 
The herbomineral formulation was divided into two parts. 
One part of the test formulation did not receive any sort of 
treatment and was defined as the control group, while the 
Biofield Energy Treatment was given to the herbomineral 
formulation defined as the treated formulation group. The 
Biofield Energy Treatment was provided through a group of 
twenty Biofield Energy Healers (The Trivedi Effect
®
), 
eighteen of which were remotely located in the U.S.A. and 
two of which were remotely located in Canada, while the test 
formulation was located in the research laboratory of Dabur 
Research Foundation near New Delhi in Ghaziabad, India. 
This Biofield Treatment was administered for 5 minutes 
through the Healers’ unique Energy Transmission process 
remotely to the test formulation under standard laboratory 
conditions. None of the Biofield Energy Healers in this study 
visited the laboratory in person, nor had any contact with the 
herbomineral samples. Further, the control group was treated 
by a “sham” healer for comparative purposes. The sham 
healer did not have any knowledge about the Biofield Energy 
Treatment. After that, the Biofield Energy treated and 
untreated test formulations were kept in similar sealed 
conditions and used for the in vitro study on splenocyte cells 
for cytokines estimation. 
2.5. Experimental Design 
The experimental study was divided into 7 groups. Group 
1 comprised of the splenocyte cells without LPS and was 
denoted as the negative control. Group 2 served as a 
stimulant group that includes cells with LPS. Group 3 
included the splenocyte cells with LPS along with vehicle 
(0.005% DMSO) and was denoted as the vehicle control. 
Groups 4 and 5 were defined as the positive control, which 
includes cells with Con-A (0.5 µg/mL) and rapamycin (1 
nm and 10 nm), respectively. Groups 6 and 7 were denoted 
as the test item groups that included splenocyte cells with 
LPS along with the untreated and Biofield Treated 
formulations, respectively, at concentration 0.00001053 to 
10.53 µg/mL. After 48 hours of incubation, supernatants 
were analyzed for the secreted levels of TNF-α, MIP-1α, 
and IL-1β using ELISA as per the manufacturer’s 
instructions. Concentrations were determined in triplicate 
wells of each sample. 
2.6. Isolation of Murine Splenocytes 
C57BL/6 male mice were sacrificed and the spleens were 
aseptically removed and grounded by passing them through a 
sterile plastic strainer under aseptic conditions. After the cells 
were centrifuged twice at 1000 g for 5 minutes, erythrocytes 
were lysed by a lysis buffer (0.15 M NH4Cl, 0.01 M 
NaHCO3, and 0.1 mM EDTA, pH 7.4) and then the cell 
pellets were washed twice with the RPMI-1640 medium. 
Further, the cells were re-suspended in the complete RPMI-
1640 medium (RPMI 1640 medium plus 10% fetal bovine 
serum, 2 mM glutamine, 100 IU/mL of penicillin and 
streptomycin, 15 mM HEPES and 50 mM 2-
mercaptoethanol). The cell counts were performed using a 
hemocytometer and cell viability was determined using the 
trypan-blue dye exclusion technique with the results showing 
≥95% of viable cells. The cells were cultured in 96-well 
tissue culture plates with 0.2 x 10
6
 cells per well. They were 
incubated at 37°C in a humidified atmosphere of 5% CO2 for 
the indicated period [36]. 
2.7. Cell Culture and Test Formulation Treatment 
Splenocyte (0.2 x 10
6
 cells per well) cells were grown in 
96-well culture plates using a RPMI-1640 medium 
supplemented with 10% FBS, 100 units/mL of penicillin, and 
100 µg/mL of streptomycin. LPS (50 ng/mL) induced 
splenocyte cells cultures were grown for 48 hours at 37°C in 
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a humidified CO2 incubator (5% CO2). The effect of 
cytotoxicity of the formulation was tested by treating cells 
with different concentrations of the test formulation in 
RPMI-1640 medium. The various concentrations of the test 
formulation were used i.e. 0.00001053 µg/mL to 10.53 
µg/mL in the presence of inflammatory stimulus (LPS) for 
cell viability assay. The respective vehicle controls (DMSO) 
were kept in the assay for comparison. 
2.8. Cytotoxicity by MTT Assay 
The effect of the Biofield Treated and untreated 
formulations at the concentration range of 0.00001053 
µg/mL to 10.53 µg/mL were tested for cell viability using 3-
(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assay. The number of viable cells were determined by 
the ability of mitochondria to convert MTT to formazan dye. 
Splenocyte cells were cultured overnight in 96-well plates, at 
a density of 0.2 x 10
6
 cells per well. After treatment with the 
test formulation and incubation period, the medium was 
removed. 20 µL of 5 mg/mL MTT was then added to each 
well and incubated for 3 hours further at 37ºC in a humidified 
5% CO2 atmosphere. The cells were centrifuged and 
supernatants were removed. The cell pellet in each well was 
resuspended in 150 µL of DMSO to dissolve formazan 
crystals. The optical density of each well was read at 540 nm 
using BioTek Reader (SIAFRT/Synergy HT multimode 
reader, US). 
The effect of the formulation on cell viability of splenocyte 
cells was determined in equation (1): 
%	Cell	viability = 100 −%	cytotoxicity (1) 
Where; % cytotoxicity = [(O.D. of control cells – O.D. of 
cells treated with the test formulation)/O.D. of control 
cells]*100. 
The concentration that resulted in >75% viability was 
selected for subsequent cytokine estimation. 
2.9. Determination of Cytokines (TNF-α, IFN-γ, and IL-1β) 
and Chemokine (MIP-1α) Using ELISA 
The in vitro activity of the Biofield Treated and untreated 
test formulations were estimated on the mice splenocyte cells 
for the production of TNF-α, IFN-γ, MIP-1α, and IL-1β using 
enzyme-linked immunosorbent assay (ELISA). The ELISA 
plates were coated with an antibody in a coating buffer at the 
recommended concentration and kept overnight at 4ºC. After 
washing with PBS-T (PBS with 0.05% Tween 20), the plates 
were blocked with assay diluent for at least 2 hours at room 
temperature. A total of 100 µL culture supernatant from 
different experimental samples and standards were incubated 
overnight at 4ºC and, after three washes, biotinylated anti-
mice cytokine (TNF-α, IFN-γ, MIP-1α, and IL-1β) antibodies 
at the recommended concentrations were incubated for 1 
hour at room temperature and the plate was incubated for 45 
minutes at room temperature with gentle shaking. The plates 
were again washed 3 times and then 100 µL of horseradish 
per-oxidase (HRP)–streptavidin conjugate solution was 
added and the plate was incubated for 45 minutes at room 
temperature with gentle shaking. Next, the plate wells were 
washed 3 times as previous and 100 µL of 3,3,5,5'-
tetramethylbenzidine (TMB) one-step substrate reagent was 
added, followed by a 30-minute incubation at room 
temperature in the dark. Further, 50 µL of 0.2 mole/L 
sulphuric acid was added to each well to stop the reaction 
and the plates were read for absorbance at 450 nm using a 
BioTek Reader (SIAFRT/Synergy HT multimode reader). 
Standards were run in parallel to the samples, and the 
concentrations were determined in triplicates for each sample 
[37]. 
2.10. Statistical Analysis 
Data were expressed as mean ± standard error of mean 
(SEM) and were subjected to one-way analysis of variance 
(ANOVA) followed by Dunnett’s test and Student’s t-test for 
two groups comparison. Statistical significance was 
considered at p≤0.05. 
3. Results and Discussion 
3.1. In Vitro Splenocyte Cells Viability by MTT Assay 
In vitro splenocyte cells viability was performed after 48 
hours using MTT assay, and the results were presented in 
Figure 1 with respect to the positive control, vehicle control, 
and the test formulation at different tested concentrations. 
The results showed a significant change in percentage of cell 
viability after the Biofield Energy Treatment in the tested 
concentrations of the formulation. Con-A and rapamycin 
showed immunostimulatory and immunosuppressive action, 
respectively, and used as the positive control in the 
experiment. The untreated cells, LPS, and Con-A group 
showed 100%, 187.7%, and 94.9% cell viability, 
respectively. The vehicle control group reported with 100% 
cell viability and the rapamycin group showed values of 
136.8%, 132.3%, 136.5%, and 120.5% at concentrations 
0.01, 0.1, 1 and 10 nM, respectively. With respect to the 
vehicle control, the percentage of cell viability was increased, 
which might be due to proliferation in the cell culture. The 
tested concentration range of the herbomineral test 
formulation was selected as 0.00001053 to 10.53 µg/mL on 
splenocyte cells. The test formulation was found safe at all 
the tested concentrations, with percentage viability ranging 
from 88.6% to 187.2%. Based upon this result, all the tested 
concentrations of the herbomineral formulation were selected 
for the estimation of cytokines. The maximum cell viability 
in cases of the untreated and treated test formulations was 
reported as 187.2% (at 0.1053 µg/mL) and 152% (at 
0.0001052 µg/mL), respectively. However, the percentage of 
cell viability in the Biofield Treated test formulation was 
increased by 29%, 52%, 13.5%, and 13.7% at concentrations 
0.00001053, 0.0001053, 0.001053, and 1.053 µg/mL, 
respectively in comparison to the vehicle control group. 
Overall, it can be concluded that the Biofield Treated test 
formulation showed increased cell viability with respect to 
the vehicle control group. 
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Figure 1. MTT assay in mice splenocyte cells after 48-hours of treatment with different Biofield Treated and untreated test formulation concentrations in the 
presence of 0.5 µg/mL LPS. The absorbance of the MTT formazan was determined at 540 nm in an ELISA reader. Cell viability was defined as the absorbance 
ratio (expressed as a percentage) of the treated cells relative to the untreated vehicle control group. 
Overall, the results of MTT assay recommend that the test 
formulation was safe at all the tested concentration ranges 
(i.e. from 0.00001053 to 10.53 µg/mL) on the basis of 
percentage in vitro viability of splenocyte cells. With respect 
to the vehicle control, all the tested herbomineral formulation 
groups showed increased cell viability. This assay defines the 
metabolic activity by evaluating the activity of succinate 
dehydrogenase, a mitochondrial enzyme. 
However, the percentage of cell viability was significantly 
increased after the Biofield Energy Treatment was provided 
to the test formulation. MTT assay was regarded as the 
standard test for evaluating cell viability [38]. This assay is 
widely used in the in vitro evaluation of the cell toxicity for 
any formulations and is regarded as a more rapid, less costly, 
less time-consuming, and nonradioactive method as 
compared with the other assays. This assay shows cell 
proliferation results on the basis of cell growth and metabolic 
activity [39]. 
3.2. Effect of Biofield Treated Formulation on the 
Expression of Pro-inflammatory Cytokines (TNF-α, 
IFN-γ, and IL-1β) and Chemokine (MIP-1α) 
The effect of the Biofield Treated herbomineral 
formulation was observed on the pro-inflammatory cytokines 
TNF-α, IFN-γ, MIP-1α, and IL-1β. All are responsible for 
inflammation, immune modulation, and lymphocyte 
activation, so it might be expected that the herbomineral 
formulations could modulate the expression and activation of 
cytokines. Therefore, the expression of TNF-α, IFN-γ, MIP-
1α, and IL-1β at six concentrations was examined in mice 
splenocyte cells. The effect of the test formulation on pro-
inflammatory cytokines was estimated by incubating various 
concentrations of the treated and untreated test formulations 
for 48 hours using ELISA assay. 
3.2.1. Estimation of TNF-α Expression 
The cytokine analysis on TNF-α secretion in splenocyte 
cells in the presence of the Biofield Treated and untreated test 
formulations are represented in the Figure 2. Data suggested 
that both the untreated and Biofield Treated test formulation 
groups demonstrated a significant suppression of TNF-α 
secretion at different tested concentrations i.e. at 0.00001053 
to 10.53 µg/mL. The negative control (untreated cells), LPS, 
Con-A, and vehicle control groups showed TNF-α values as 
74.04 ± 5.40, 154.49 ± 3.06, 381.09 ± 36.24, and 323.08 ± 
10.60 pg/mL, respectively. However, the untreated test 
formulation demonstrated a significant suppression of TNF-α 
from LPS stimulated levels at all the tested concentrations i.e. 
at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 1.053 
and 10.53 µg/mL by 23.51%, 22.12%, 12.80%, 13.69%, 
22.22%, 24.31%, and 30.46%, respectively as compared with 
the vehicle control. Further, the Biofield Treated test 
formulation also showed significant inhibition of TNF-α at all 
concentrations i.e. at 0.00001053, 0.0001053, 0.001053, 
0.01053, 0.1053, 1.053 and 10.53 µg/mL by 16.87%, 17.36%, 
14.29%, 10.62%, 28.57%, 20.84%, and 24.90%, respectively 
as compared to the vehicle control group. In addition, at two 
tested concentrations i.e. at 0.001053 and 0.1053 µg/mL, the 
Biofield Treated test formulation showed suppression by 
1.70% and 8.16%, respectively as compared with the untreated 
test formulation. On the other hand, the Biofield Treated test 
formulation demonstrated an increase in TNF-α levels at five 
tested concentrations i.e. 0.00001053, 0.0001053, 0.01053, 
1.053, and 10.53 µg/mL by 8.69%, 6.12%, 3.56%, 4.59%, and 
7.98%, respectively as compared to the untreated test 
formulation. 
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Figure 2. Concentration-dependent effect on TNF-α by the Biofield Treated and untreated test formulations. For each concentration treatment, the level of 
TNF-α release was measured after 48 hours of treatment. All the values are represented in pg/mL as mean ± SEM. 
Overall, it can be suggested that the Biofield Treated 
formulation has significant immunosuppressive activity by 
inhibiting the concentration of TNF-α as compared with the 
vehicle control, while the Biofield Treatment has also shown 
an alteration in the concentration of TNF-α as compared with 
the untreated formulation. The Biofield Treatment showed 
significant effect on altering the level of TNF-α as compared 
to the untreated test formulation. For most immune disorders, 
TNF-α is the major factor that controls many disease 
pathologies [40, 41]. The role of TNF-α and its alterations 
have been significantly reported to improve insulin 
resistance, lipid profiles, etc. in patients’ chronic 
inflammatory diseases [42]. So, it can be suggested that the 
Biofield Treated test formulation can be used in many 
inflammatory disorders by controlling the expression of 
TNF-α. 
 
Figure 3. Concentration-dependent effect of LPS mediated production of IFN-γ by the Biofield Treated formulation. For each concentration treatment, the 
level of IFN-γ release was measured after 48-hours of treatment. The values are represented in pg/mL as mean ± SEM (***p≤0.001 and **p≤0.01 as compared 
with the untreated test formulation). 
3.2.2. Estimation of IFN-γ Expression 
Estimation of IFN-γ expression in mice splenocyte cells 
after treatment with the Biofield Treated and untreated test 
formulations are represented in Figure 3. The results show 
that in the test formulation groups there was significant 
inhibition of IFN-γ expression as compared with the vehicle 
control group, while the Biofield Treated test formulation 
further enhanced the immunosuppression at most of the 
concentrations. The negative control (untreated cells), Con-
A, LPS, and vehicle control group showed IFN-γ values as 
18.47 ± 0.44, 53.73 ± 1.73, 48.80 ± 0.64, and 39.67 ± 4.04 
pg/mL, respectively. However, the untreated test formulation 
demonstrated significant suppression of IFN-γ from LPS 
stimulated levels at all the tested formulation concentrations 
i.e. at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 
1.053 and 10.53 µg/mL by 37.66%, 42.20%, 40.01%, 
33.28%, 37.48%, 37.81%, and 44.21%, respectively as 
compared with the vehicle control. Further, the Biofield 
Treated test formulation also showed significant inhibition of 
IFN-γ at all concentrations i.e. at 0.00001053, 0.0001053, 
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0.001053, 0.01053, 0.1053, 1.053 and 10.53 µg/mL by 
45.22%, 43.53%, 35.14%, 38.82%, 43.21%, 42.70%, and 
42.85%, respectively as compared to the vehicle control 
group. At five tested concentrations i.e. at 0.00001053, 
0.0001053, 0.01053, 0.1053, and 1.053 µg/mL, the Biofield 
Treated test formulation showed further suppression of IFN-γ 
by 12.63%, 2.31%, 8.31%, 9.15%, and 7.86% as compared 
with the untreated test formulation. However, the Biofield 
Treated test formulation demonstrated increase in IFN-γ 
levels at two tested formulation concentrations i.e. 0.001053 
and 10.53 µg/mL by 8.11% and 2.44%, respectively as 
compared to the untreated test formulation. 
Various literature suggests that IFN-γ expression plays a 
key role in the regulation of visceral adipose tissue 
inflammatory response [43], inflammation, and glucose 
homeostasis [44], as well as in the inhibition of the 
inflammatory response of macrophages cells (in IFN-γ 
deficiency condition) [45] and many other important 
inflammatory disorders. So, it can be concluded that the 
Biofield Treated test formulation would be a better 
alternative and complementary herbomineral supplement 
with respect to inflammatory disorders. 
3.2.3. Estimation of MIP-1α Expression 
The effect of the Biofield Treated test formulation on 
MIP-1α secretion levels is shown in Figure 4. The figure 
demonstrates that the Biofield Treated and untreated test 
formulations inhibit the expression of MIP-1α in all the 
tested concentrations as compared with the vehicle control 
group. The untreated cells, Con-A, LPS, and vehicle control 
group showed values of MIP-1α as 32.84 ± 7.32, 1639.71 ± 
15.10, 1374.02 ± 15.71, and 1167.65 ± 16.32 pg/mL, 
respectively. The untreated test formulation showed 
significant inhibition of MIP-1α secretion at six tested 
concentrations out of seven i.e. at 0.00001053, 0.0001053, 
0.001053, 0.1053, 1.053, and 10.53 µg/mL by 7.45%, 
1.51%, 11.84%, 5.92%, 17.73%, and 14.74%, respectively 
as compared to the vehicle control group. However, the 
Biofield Treated test formulation group reported inhibition 
of MIP-1α secretion at 0.00001053, 0.0001053, 0.01053, 
0.1053, 1.053, and 10.53 µg/mL by 6.59%, 9.69%, 13.22%, 
14.11%, 7.13%, and 9.78%, respectively as compared with 
the vehicle control group. The Biofield Treatment further 
enhanced the immunosuppressive property of the test 
formulation at three tested concentrations i.e. at 0.0001053, 
0.01053, and 0.1053 by 8.31%, 21.53%, and 8.70%, 
respectively as compared with the untreated test 
formulation. The rest of the other Biofield Treated test 
formulation concentrations showed increased levels of 
MIP-1α as compared with the untreated test formulation. 
The comparative effect of the Biofield Treated and 
untreated test formulation showed altered levels of MIP-1α 
in splenocyte cells at all the tested concentrations. 
 
Figure 4. Concentration-dependent effect of LPS mediated production of MIP-1α by the Biofield Treated test formulation. For each concentration treatment, 
the level of MIP-1α release was measured after 48-hours of treatment. The values are represented in pg/mL as mean ± SEM (**p≤0.01 and *p≤0.05, as 
compared with the untreated test formulation). 
Literature reports suggest that MIP-1α reduction could be 
beneficial in minimizing the inflammatory responses in 
several diseases [46]. Additionally, MIP-1α also plays an 
important role in mediating the acute inflammatory response 
in trauma hemorrhages [47]. Overall, in respect to the 
suppression of MIP-1α in the Biofield Treated test 
formulation group, the data suggest the importance of the 
Biofield Treated formulation in many clinical conditions. 
3.2.4. Estimation of IL-1β Expression 
The expression of IL-1β in mice splenocytes in the 
presence of the Biofield Treated test formulation and the 
untreated test formulation is demonstrated in Figure 5. The 
comparative effect of the Biofield Treated and untreated test 
formulations on IL-1β secretion in splenocyte cells showed 
significant inhibition at all the tested concentrations with 
respect to the vehicle control. The untreated cells, Con-A, 
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LPS, and vehicle control group showed values of IL-1β as 
19.76 ± 1.13, 41.30 ± 1.06, 33.50 ± 1.55, and 35.37 ± 3.94 
pg/mL, respectively. The untreated test formulation showed 
significant inhibition of IL-1β secretion at all the tested 
concentrations i.e. at 0.00001053, 0.0001053, 0.001053, 
0.01053, 0.1053, 1.053, and 10.53 µg/mL by 6.67%, 15.63%, 
25.75%, 25.75%, 37.23%, 26.91%, and 34.94%, respectively 
as compared with the vehicle control group. The Biofield 
Treated formulation also showed significant inhibition of IL-
1β secretion at all the tested concentrations i.e. at 
0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 1.053, 
and 10.53 µg/mL by 25.07%, 7.38%, 8.06%, 18.86%, 
17.25%, 22.53%, and 31.34%, respectively as compared with 
the vehicle control group. However, at a lower concentration 
(0.00001053 µg/mL), the Biofield Treatment formulation 
further improved the immunosuppressive property and 
showed significantly decreased IL-1β secretion by 19.72% as 
compared with the untreated test formulation, while with the 
rest of the tested concentrations, the percentage was 
increased with respect to the untreated test formulation in all 
the concentrations of the test formulation. 
 
Figure 5. Concentration-dependent effect of LPS mediated production of IL-1β by the Biofield Treated formulation. For each concentration treatment, the 
level of IL-1β release was measured in cell supernatant after 48 hours of treatment. All values are represented in pg/mL as mean ± SEM (**p≤0.01, as 
compared with the untreated test formulation). 
Overall, the results suggest that higher concentrations of 
the test formulation showed better immunosuppressive 
activity with respect to lower tested concentrations of the 
herbomineral test formulation. The importance of IL-1β 
expression in immunological and inflammatory functions 
during infections are well established [48, 49]. The inhibitory 
effect of the Biofield Treated test formulation might play an 
important role in mediating autoinflammatory diseases as a 
Complementary and Alternative Medicine (CAM) approach. 
The scope of herbal and traditional medicine has been 
continuously increasing in developing countries [50], but the 
Biofield Energy Healing model has shown to be a novel 
therapeutic intervention approach that must still be 
incorporated and utilized in conventional as well as 
complementary and alternative medicine. The herbomineral 
formulation treated with Biofield Energy Healing showed 
significant immunomodulatory action and the results suggest 
that the Biofield Treated formulation can be the best 
alternative medicine for many inflammatory disorders. The 
individual components of the test formulation (ashwagandha, 
zinc, magnesium, and selenium) have already been reported 
to have immune modulatory properties. Ashwagandha has 
been reported to regulate the immune system by inhibiting 
the NF-κB and AP-1 transcription factors in human 
peripheral blood and synovial fluid mononuclear cells [49]. 
Further, zinc deficiency plays an important role in cytokines 
generation, such as IL-2, IL-6, IL-1β, and TNF-α, and acts in 
a concentration dependent manner by inhibiting the 
activation of NF-κB [50]. Similarly, magnesium also 
regulates the immune system through the activation of NF-
κB and generation of cytokines, which can be effectively 
applicable in inflammatory conditions or their related disease 
pathogenesis [51]. However, selenium regulates various 
leukocytes effector functions such as cytokines secretion, 
migration, adherence, and phagocytosis with the help of 
calcium flux and oxidative pathway in innate immunity [52-
54]. 
Overall, the results suggest that the Biofield Energy 
Treated test formulation can be used to treat many 
inflammatory disorders with little-to-no toxicity. Literature 
reports the significant outcomes of Biofield Energy Healing 
with respect to cytokines inhibition in cancer cell lines [55]. 
It might be suggested that the Biofield Treated test 
formulation can significantly inhibit the T and B 
lymphocytes, which might be used to improve 
immune/autoimmune disorders, stress, and asthma. 
4. Conclusions 
Based on the obtained results, it was concluded that the 
Biofield Energy Treated test formulation modulates the 
splenocyte cells function with respect to the pro-
inflammatory cytokines TNF-α, IFN-γ, MIP-1α, and IL-1β. 
However, the Biofield Treated test formulation significantly 
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inhibited the activity of pro-inflammatory cytokines with 
respect to the untreated test formulation. In vitro cells 
viability assay showed that all the tested concentrations of 
the herbomineral formulation were found safe with respect to 
the vehicle control group. The percentage cell viability 
ranged from 88.9% to 187.2% in different concentration 
ranges of the test formulation, so concentration ranges from 
0.00001053 to 10.53 µg/mL of the test formulation were 
selected for the splenocyte cells for the cytokines estimation. 
TNF-α levels were significantly inhibited at 0.001053 and 
0.1053 µg/mL, in which the Biofield Treated test formulation 
group showed suppression by 1.70% and 8.16% as compared 
with the untreated test formulation. Similarly, significant 
suppression of IFN-γ expression was reported at five 
concentrations i.e. at 0.00001053, 0.0001053, 0.01053, 
0.1053, and 1.053 µg/mL of the Biofield Treated test 
formulation by 12.63%, 2.31%, 8.31%, 9.15%, and 7.86%, 
respectively as compared with the untreated test formulation. 
This might help in inflammatory tissue response and can be 
used in many inflammatory disorders. In the case of MIP-1α 
secretion, the expression was inhibited by the Biofield 
Treated test formulation at three tested concentrations i.e. at 
0.0001053, 0.01053, and 0.1053 µg/mL by 8.31%, 21.53%, 
and 8.70%, respectively as compared with the untreated test 
formulation. IL-1β secretion was significantly suppressed 
only at a very low concentration i.e. 0.00001053 µg/mL by 
19.72% as compared with the untreated test formulation. 
On the basis of the experimental results of the various 
tested cytokines showed significant immunosuppressive 
activity in the new herbomineral formulation after treatment 
with The Trivedi Effect
® 
- Biofield Energy Healing (TEBEH) 
by the group of twenty renowned Biofield Energy Healers. 
Overall, The Trivedi Effect
® 
- Biofield Energy Healing 
Treated test formulation significantly inhibited the activity of 
pro-inflammatory cytokines and showed immunosuppressive 
activity with a safe therapeutic index as compared with the 
untreated test formulation. Biofield Energy Healing shows 
great promise as a complementary and alternative medicine 
therapy and might play an important role in autoimmune and 
inflammatory diseases like Chronic peptic ulcers, 
Tuberculosis, Hepatitis, Celiac Disease (gluten-sensitive 
enteropathy), Addison Disease, Irritable Bowel Syndrome, 
Multiple Sclerosis (MS), Parkinson’s Disease, Graves’ 
Disease, Rheumatoid arthritis, Chronic periodontitis, 
Ulcerative colitis, Crohn's disease, Chronic sinusitis, Lupus, 
Systemic Lupus Erythematosus, Hashimoto Thyroiditis Type 
1 Diabetes, Asthma, Chronic active hepatitis, Myasthenia 
Gravis, Rheumatoid Arthritis, Reactive Arthritis, Pernicious 
and Aplastic Anemia, Sjogren Syndrome, Alopecia Areata, 
Psoriasis, Scleroderma, Fibromyalgia, Chronic Fatigue 
Syndrome, Vitiligo, Vasculitis, Alzheimer’s Disease, 
Atherosclerosis, Dermatitis, Diverticulitis, stress, etc. 
Biofield Energy Healing may also be useful in the prevention 
of immune-mediated tissue damage in cases of organ 
transplants (for example heart transplants, kidney transplants 
and liver transplants), stress prevention and management, for 
anti-aging and in improving overall health and quality of life. 
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